SANUWAVE Health, Inc. (SNWV)

US — Healthcare Sector
Peers: NNOX  QTRX  CVRX  MASS  BWAY  VMD  HUMA  SOPH  OM  MGRM 

Automate Your Wheel Strategy on SNWV

With Tiblio's Option Bot, you can configure your own wheel strategy including SNWV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SNWV
  • Rev/Share 4.5776
  • Book/Share -1.7257
  • PB -17.6392
  • Debt/Equity -0.08
  • CurrentRatio 0.4337
  • ROIC 0.5433

 

  • MktCap 260810072.0
  • FreeCF/Share -0.0124
  • PFCF -2460.4724
  • PE -6.8537
  • Debt/Assets 0.0358
  • DivYield 0
  • ROE 1.448

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SNWV Northland Capital -- Outperform -- $55 Sept. 3, 2025
Initiation SNWV Roth Capital -- Buy -- $49 July 29, 2025

News

Sanuwave Health Inc. (SNWV) to Report Q3 Results: Wall Street Expects Earnings Growth
SNWV
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Sanuwave Health (SNWV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Sanuwave Health Inc. (SNWV) to Report Q3 Results: Wall Street Expects Earnings Growth
Sanuwave: A Long-Term Compounder In Its Early Stages
SNWV
Published: September 15, 2025 by: Seeking Alpha
Sentiment: Positive

Sanuwave's UltraMIST system is gaining significant traction for wound treatment, driven by its razor and razor blade business model. Q2 revenue grew 42% year over year, with full year guidance calling for 50% growth at the midpoint. Q2 gross margin was 78.3% and is expected to gradually increase in the coming quarters due to lower manufacturing costs.

Read More
image for news Sanuwave: A Long-Term Compounder In Its Early Stages
SANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call Transcript
SNWV
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral

SANUWAVE Health, Inc. (NASDAQ:SNWV ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Morgan C. Frank - CEO & Chairman Peter Sorensen - CFO & Secretary Conference Call Participants Albert Hanser - Unidentified Company Christopher Michael Plahm - Tall Pines Capital, LLC Kyle Royal Bauser - ROTH Capital Partners, LLC, Research Division Operator Good day, everyone, and welcome to the SANUWAVE Q2 Earnings Call.

Read More
image for news SANUWAVE Health, Inc. (SNWV) Q2 2025 Earnings Call Transcript
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
SNWV
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations.

Read More
image for news Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations

About SANUWAVE Health, Inc. (SNWV)

  • IPO Date 2009-09-30
  • Website https://www.sanuwave.com
  • Industry Medical - Devices
  • CEO Morgan C. Frank
  • Employees 46

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.